MX2013010379A - Uso de inhibidores de receptores de la familia egfr en el tratamiento de canceres de mama refractarios a hormonas. - Google Patents

Uso de inhibidores de receptores de la familia egfr en el tratamiento de canceres de mama refractarios a hormonas.

Info

Publication number
MX2013010379A
MX2013010379A MX2013010379A MX2013010379A MX2013010379A MX 2013010379 A MX2013010379 A MX 2013010379A MX 2013010379 A MX2013010379 A MX 2013010379A MX 2013010379 A MX2013010379 A MX 2013010379A MX 2013010379 A MX2013010379 A MX 2013010379A
Authority
MX
Mexico
Prior art keywords
inhibitor
erbb3
patient
hormone refractory
refractory breast
Prior art date
Application number
MX2013010379A
Other languages
English (en)
Inventor
Gabriela Garcia
William Kubasek
Victor Moyo
Gavin Macbeath
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of MX2013010379A publication Critical patent/MX2013010379A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan métodos para suprimir el crecimiento de tumores de mama refractarios a hormonas al poner en contacto las células tumorales con un inhibidor de ErbB3, preferentemente un anticuerpo anti-ErbB3. También se proporcionan métodos para tratar cáncer de mama refractario a hormonas en un paciente mediante la administración al paciente de un inhibidor de heregulina que se une a ErbB3 o al heterodímero ErbB2/ErbB3, el inhibidor es un anticuerpo anti-ErbB3 o un anticuerpo anti-ErbB2. Los métodos de tratamiento pueden comprender además seleccionar un paciente que tiene un cáncer de mama refractario a hormonas y luego administrar el inhibidor al paciente. Los métodos de tratamiento también pueden comprender administrar un antagonista del receptor de estrógenos, o un inhibidor de aromatasa a la patente y puede comprender adicionalmente administrar al paciente al menos un agente anticanceroso adicional que no es un inhibidor de ErbB3, un antagonista del receptor de estógenos o un inhibidor de aromatasa al paciente en combinación con el inhibidor de ErbB3.
MX2013010379A 2011-03-11 2012-03-12 Uso de inhibidores de receptores de la familia egfr en el tratamiento de canceres de mama refractarios a hormonas. MX2013010379A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161451848P 2011-03-11 2011-03-11
US201261604281P 2012-02-28 2012-02-28
PCT/US2012/028792 WO2012125573A2 (en) 2011-03-11 2012-03-12 Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers

Publications (1)

Publication Number Publication Date
MX2013010379A true MX2013010379A (es) 2014-03-27

Family

ID=45894680

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010379A MX2013010379A (es) 2011-03-11 2012-03-12 Uso de inhibidores de receptores de la familia egfr en el tratamiento de canceres de mama refractarios a hormonas.

Country Status (12)

Country Link
US (1) US20140134170A1 (es)
EP (1) EP2683741A2 (es)
JP (1) JP2014508782A (es)
KR (1) KR20140044796A (es)
CN (1) CN103562226A (es)
AU (1) AU2012229147B2 (es)
BR (1) BR112013022882A2 (es)
CA (1) CA2828075A1 (es)
EA (1) EA201300996A1 (es)
MX (1) MX2013010379A (es)
SG (1) SG192844A1 (es)
WO (1) WO2012125573A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2431940T3 (es) 2007-02-16 2013-11-28 Merrimack Pharmaceuticals, Inc. Anticuerpos contra la ERBB3 y usos de los mismos
SG183532A1 (en) 2010-03-11 2012-09-27 Merrimack Pharmaceuticals Inc Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
US9527913B2 (en) 2012-05-02 2016-12-27 Symphogen A/S Humanized pan-HER antibody compositions
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
NZ724013A (en) 2014-02-28 2019-11-29 Merus Nv Antibodies that bind egfr and erbb3
CN113101292B (zh) * 2014-05-08 2023-07-11 上海市生物医药技术研究院 双炔失碳酯组合物和疾病治疗方法
KR20170137886A (ko) 2015-04-17 2017-12-13 메리맥 파마슈티컬즈, 인크. 세리반투맙에 의한 병용 치료
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
ITUB20160828A1 (it) * 2016-02-18 2017-08-18 Univ Degli Studi Genova Utilizzo di una dieta che mima il digiuno per potenziare l'efficacia di antiestrogeni nella terapia del cancro
US20190091227A1 (en) * 2016-03-15 2019-03-28 Merrimack Pharmaceuticals, Inc. Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
US20190231718A1 (en) 2016-10-11 2019-08-01 Duke University Treatment of breast cancer
CN110267656B (zh) * 2017-01-10 2023-01-31 王巍 拉索昔芬调节膜结合***信号的应用及治疗癌症的方法
WO2018182422A1 (en) 2017-03-31 2018-10-04 Merus N.V. Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
CA3063849A1 (en) * 2017-05-17 2018-11-22 Merus N.V. Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
SG11202001050PA (en) 2017-08-09 2020-03-30 Merus Nv Antibodies that bind egfr and cmet
WO2019185164A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Her3 antigen-binding molecules
WO2019199891A1 (en) 2018-04-10 2019-10-17 Duke University Lasofoxifene treatment of breast cancer
WO2022078490A1 (zh) * 2020-10-15 2022-04-21 上海翰森生物医药科技有限公司 抗erbb3抗体或其抗原结合片段及其医药用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CA2245835A1 (en) 1995-06-14 1997-01-03 The Regents Of The University Of California Novel high affinity human antibodies to tumor antigens
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US7390632B2 (en) 1999-09-30 2008-06-24 Tumor Biology Investment Group, Inc. Soluble ErbB3 receptor isoforms
US7612042B2 (en) 2001-05-31 2009-11-03 Tumor Biology Investment Group, Inc. Methods for inhibiting heregulin and treating cancer
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
EP2400021B1 (en) 2002-03-26 2016-11-30 Zensun (Shanghai) Science & Technology, Co., Ltd. ErbB3 based methods and compositions for treating neoplasms
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US7332585B2 (en) * 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
ES2431940T3 (es) 2007-02-16 2013-11-28 Merrimack Pharmaceuticals, Inc. Anticuerpos contra la ERBB3 y usos de los mismos
MX2009008909A (es) 2007-03-01 2009-08-28 Symphogen As Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico.
NZ581201A (en) 2007-05-11 2012-05-25 Enzon Pharmaceuticals Inc Rna antagonist compounds for the modulation of her3
CA2721093A1 (en) 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
UA104868C2 (uk) 2008-08-15 2014-03-25 Меррімак Фармасьютікалз, Інк. Спосіб лікування пацієнта, що має неопластичну пухлину, відповідно до спрогнозованої реакції
WO2010059315A1 (en) * 2008-11-18 2010-05-27 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
NZ594665A (en) 2009-03-20 2013-08-30 Genentech Inc Bispecific anti-her antibodies
AU2010242914B2 (en) 2009-04-29 2014-11-13 Trellis Bioscience, Llc Improved antibodies immunoreactive with heregulin-coupled HER3
WO2011047180A1 (en) * 2009-10-14 2011-04-21 Merrimack Pharmaceuticals, Inc. Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof
SG183532A1 (en) * 2010-03-11 2012-09-27 Merrimack Pharmaceuticals Inc Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
AR080873A1 (es) 2010-04-09 2012-05-16 Aveo Pharmaceuticals Inc Anticuerpos contra factor de crecimiento epidermico (anti-erbb3 o anti-her3)
AR084469A1 (es) * 2010-07-09 2013-05-22 Exelixis Inc Combinaciones de inhibidores de quinasas para el tratamiento del cancer

Also Published As

Publication number Publication date
NZ614427A (en) 2015-08-28
WO2012125573A3 (en) 2012-12-27
EA201300996A1 (ru) 2014-01-30
JP2014508782A (ja) 2014-04-10
SG192844A1 (en) 2013-09-30
EP2683741A2 (en) 2014-01-15
CA2828075A1 (en) 2012-09-20
US20140134170A1 (en) 2014-05-15
AU2012229147A1 (en) 2013-03-14
WO2012125573A2 (en) 2012-09-20
CN103562226A (zh) 2014-02-05
KR20140044796A (ko) 2014-04-15
BR112013022882A2 (pt) 2016-12-20
AU2012229147B2 (en) 2015-12-24

Similar Documents

Publication Publication Date Title
MX2013010379A (es) Uso de inhibidores de receptores de la familia egfr en el tratamiento de canceres de mama refractarios a hormonas.
MX344355B (es) Uso de inhibidores de erbb3 en el tratamiento de canceres de mama triple negativos y de tipo basal.
MX2012011718A (es) Anticuerpos anti-erbb3.
WO2012016133A3 (en) Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
MX2019004193A (es) Combinacion de anticuerpos anti-kir y anticuerpos anti-pd-1 para tratar cancer.
MX350861B (es) Anticuerpos frente al receptor del factor de crecimiento epidérmico (egfr) y usos de éstos.
MX2013009732A (es) Terapias de combinacion comprendiendo agentes anti-erbb3.
MX347981B (es) Composicion de anticuerpos pan-her.
PH12014502048B1 (en) Treatment of cancer with tor kinase inhibitors
PH12014502437A1 (en) Anti-egfr antibodies and uses threof
PH12014502419A1 (en) Specific binding proteins and uses thereof
IN2014KN00871A (es)
JO3291B1 (ar) الأجسام المضادة لـ csf-1r
PH12014502046A1 (en) Treatment of cancer with tor kinase inhibitors
JO3370B1 (ar) طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
AR075896A1 (es) Anticuerpos anti-her (factor de crecimiento epidermico)
WO2011146568A8 (en) Predicting response to a her inhibitor
MX2014011500A (es) Diagnosticos y tratamientos relacionados a inhibidores her3.
MY163502A (en) Antibodies specifically binding to the epidermal growth factor receptor
TR201903312T4 (tr) Benralizumab kullanarak astım alevlenme oranlarini azaltma yöntemleri.
EP2274437A4 (en) COMPOSITIONS AND METHODS FOR DETECTION OF EGFR MUTATIONS IN CASES OF CANCER
MX2021012335A (es) Anticuerpos humanos que se unen a ret y metodos de uso de los mismos.
MX2014013763A (es) Dosificacion y administracion de conjugados de scfv bi-especificos en combinacion con agentes terapeuticos anti-cancer.
NZ625758A (en) Method for treating breast cancer
IN2014CN04652A (es)